Kanaph Therapeutics Inc. (KOSDAQ:0082N0)

Market Cap	137.79B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	13.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,670
Open	9,450
Previous Close	9,400
Day's Range	9,350 - 10,740
52-Week Range	9,170 - 70,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Kanaph Therapeutics

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker ther...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2019
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 0082N0

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 16, 2026

Data Sources Report a data error